Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.Nature Communications|May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancersChendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.Molecular Cancer Therapeutics|October 13, 2010
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibodyAngela Coxon, James Bready, Hosung Min, et al.Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.Cancer Discovery|September 27, 2018
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established TherapiesSean Caenepeel, Sean P Brown, Brian Belmontes, et al.Journal of Medicinal Chemistry|March 18, 2025
From DNA-Encoded Library Screening to AM-9747: An MTA-Cooperative PRMT5 Inhibitor with Potent Oral In Vivo EfficacyIan Sarvary, Mikkel Vestergaard, Loris Moretti, et al.Cancer Discovery|September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted CancersBrian Belmontes, Katherine K Slemmons, Chun Su, et al.Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.Biorxiv : the Preprint Server for Biology|August 12, 2025
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneityT S Ramasubramanian, Pichet Adstamongkonkul, Christina M Scribano, et al.Pageof 12